Clinical and Translational Oncology

, Volume 15, Issue 3, pp 248–251 | Cite as

DeCIDE and PARADIGM: nails in the coffin of induction chemotherapy in head and neck squamous cell carcinoma?

  • S. W. LooEmail author
  • K. Geropantas
  • T. W. Roques

Induction chemotherapy was first used in squamous cell carcinoma of the head and neck (SCCHN) in the 1970s. High overall response rates were observed in previously untreated tumours [1] and a correlation between response to induction chemotherapy and favourable outcome following radiotherapy was noted [2]. Numerous subsequent randomised studies and meta-analyses nonetheless failed to demonstrate a significant survival advantage with the use of induction chemotherapy compared with locoregional treatment alone [3]. A marginally significant 5 % absolute improvement in 5 year survival was seen when analysis was restricted to studies using a platin and 5-fluorouracil (PF) as the induction regimen. This was however overshadowed by the larger survival benefit observed with concurrent chemoradiation (CRT). As a result, CRT became widely accepted as the standard of care in the non-surgical management of patients with locoregionally advanced SCCHN.

Recent years have witnessed a renewed interest...


Docetaxel Induction Chemotherapy DeCIDE Trial Slow Accrual Advanced Nodal Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest



  1. 1.
    Argiris A, Jayaram P, Pichardo D (2005) Revisiting induction chemotherapy for head and neck cancer. Oncology (Williston Park) 19:759–770Google Scholar
  2. 2.
    Ensley JF, Jacobs JR, Weaver A et al (1984) Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811–814PubMedCrossRefGoogle Scholar
  3. 3.
    Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefGoogle Scholar
  4. 4.
    Kies MS, Haraf DJ, Rosen F et al (2001) Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19:1961–1969PubMedGoogle Scholar
  5. 5.
    Posner MR, Haddad RI, Wirth L et al (2004) Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 31:778–785PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen EEW, Karrison T, Kocherginsky M et al (2012) DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:abstract 5500Google Scholar
  7. 7.
    Haddad RI, Rabinowits G, Tishler RB et al (2012) The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC). J Clin Oncol 30:abstract 5501Google Scholar
  8. 8.
    Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  1. 1.Department of OncologyNorfolk and Norwich University HospitalNorwichUK

Personalised recommendations